PMC:7113610 / 17622-19130 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"635","span":{"begin":272,"end":287},"obj":"Gene"},{"id":"636","span":{"begin":555,"end":559},"obj":"Gene"},{"id":"637","span":{"begin":1291,"end":1295},"obj":"Gene"},{"id":"638","span":{"begin":314,"end":324},"obj":"Species"},{"id":"639","span":{"begin":341,"end":349},"obj":"Species"},{"id":"640","span":{"begin":646,"end":654},"obj":"Species"},{"id":"641","span":{"begin":848,"end":858},"obj":"Species"},{"id":"642","span":{"begin":880,"end":886},"obj":"Species"},{"id":"643","span":{"begin":891,"end":895},"obj":"Species"},{"id":"644","span":{"begin":984,"end":992},"obj":"Species"},{"id":"645","span":{"begin":1037,"end":1045},"obj":"Species"},{"id":"646","span":{"begin":1199,"end":1209},"obj":"Species"},{"id":"647","span":{"begin":155,"end":165},"obj":"Chemical"},{"id":"648","span":{"begin":217,"end":227},"obj":"Chemical"},{"id":"649","span":{"begin":257,"end":268},"obj":"Chemical"},{"id":"650","span":{"begin":481,"end":491},"obj":"Chemical"},{"id":"651","span":{"begin":493,"end":505},"obj":"Chemical"},{"id":"652","span":{"begin":507,"end":516},"obj":"Chemical"},{"id":"653","span":{"begin":518,"end":529},"obj":"Chemical"},{"id":"654","span":{"begin":531,"end":542},"obj":"Chemical"},{"id":"655","span":{"begin":544,"end":553},"obj":"Chemical"},{"id":"656","span":{"begin":561,"end":572},"obj":"Chemical"},{"id":"657","span":{"begin":578,"end":585},"obj":"Chemical"},{"id":"658","span":{"begin":1320,"end":1326},"obj":"Chemical"},{"id":"659","span":{"begin":470,"end":479},"obj":"Disease"},{"id":"660","span":{"begin":633,"end":642},"obj":"Disease"},{"id":"661","span":{"begin":867,"end":876},"obj":"Disease"},{"id":"662","span":{"begin":996,"end":1004},"obj":"Disease"},{"id":"663","span":{"begin":1028,"end":1036},"obj":"Disease"},{"id":"664","span":{"begin":1484,"end":1492},"obj":"Disease"},{"id":"665","span":{"begin":1493,"end":1502},"obj":"Disease"}],"attributes":[{"id":"A635","pred":"tao:has_database_id","subj":"635","obj":"Gene:3456"},{"id":"A636","pred":"tao:has_database_id","subj":"636","obj":"Gene:22848"},{"id":"A637","pred":"tao:has_database_id","subj":"637","obj":"Gene:59272"},{"id":"A638","pred":"tao:has_database_id","subj":"638","obj":"Tax:2697049"},{"id":"A639","pred":"tao:has_database_id","subj":"639","obj":"Tax:9606"},{"id":"A640","pred":"tao:has_database_id","subj":"640","obj":"Tax:9606"},{"id":"A641","pred":"tao:has_database_id","subj":"641","obj":"Tax:2697049"},{"id":"A642","pred":"tao:has_database_id","subj":"642","obj":"Tax:9606"},{"id":"A643","pred":"tao:has_database_id","subj":"643","obj":"Tax:10090"},{"id":"A644","pred":"tao:has_database_id","subj":"644","obj":"Tax:9606"},{"id":"A645","pred":"tao:has_database_id","subj":"645","obj":"Tax:9606"},{"id":"A646","pred":"tao:has_database_id","subj":"646","obj":"Tax:2697049"},{"id":"A647","pred":"tao:has_database_id","subj":"647","obj":"MESH:C000606551"},{"id":"A648","pred":"tao:has_database_id","subj":"648","obj":"MESH:C000606551"},{"id":"A649","pred":"tao:has_database_id","subj":"649","obj":"MESH:D002738"},{"id":"A650","pred":"tao:has_database_id","subj":"650","obj":"MESH:C032855"},{"id":"A651","pred":"tao:has_database_id","subj":"651","obj":"MESH:C041747"},{"id":"A652","pred":"tao:has_database_id","subj":"652","obj":"MESH:D012254"},{"id":"A653","pred":"tao:has_database_id","subj":"653","obj":"MESH:C053539"},{"id":"A654","pred":"tao:has_database_id","subj":"654","obj":"MESH:C462182"},{"id":"A655","pred":"tao:has_database_id","subj":"655","obj":"MESH:D019438"},{"id":"A656","pred":"tao:has_database_id","subj":"656","obj":"MESH:C000596027"},{"id":"A657","pred":"tao:has_database_id","subj":"657","obj":"MESH:C086979"},{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"MESH:D007239"},{"id":"A660","pred":"tao:has_database_id","subj":"660","obj":"MESH:D007239"},{"id":"A661","pred":"tao:has_database_id","subj":"661","obj":"MESH:D007239"},{"id":"A662","pred":"tao:has_database_id","subj":"662","obj":"MESH:C000657245"},{"id":"A663","pred":"tao:has_database_id","subj":"663","obj":"MESH:D007239"},{"id":"A664","pred":"tao:has_database_id","subj":"664","obj":"MESH:C000657245"},{"id":"A665","pred":"tao:has_database_id","subj":"665","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T78","span":{"begin":945,"end":957},"obj":"Body_part"},{"id":"T79","span":{"begin":1153,"end":1161},"obj":"Body_part"},{"id":"T80","span":{"begin":1237,"end":1247},"obj":"Body_part"}],"attributes":[{"id":"A78","pred":"fma_id","subj":"T78","obj":"http://purl.org/sig/ont/fma/fma62970"},{"id":"A79","pred":"fma_id","subj":"T79","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A80","pred":"fma_id","subj":"T80","obj":"http://purl.org/sig/ont/fma/fma62871"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":945,"end":957},"obj":"Body_part"},{"id":"T7","span":{"begin":945,"end":950},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0000178"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T187","span":{"begin":314,"end":322},"obj":"Disease"},{"id":"T188","span":{"begin":314,"end":318},"obj":"Disease"},{"id":"T189","span":{"begin":470,"end":479},"obj":"Disease"},{"id":"T190","span":{"begin":633,"end":642},"obj":"Disease"},{"id":"T191","span":{"begin":848,"end":856},"obj":"Disease"},{"id":"T192","span":{"begin":848,"end":852},"obj":"Disease"},{"id":"T193","span":{"begin":867,"end":876},"obj":"Disease"},{"id":"T194","span":{"begin":996,"end":1004},"obj":"Disease"},{"id":"T195","span":{"begin":1199,"end":1207},"obj":"Disease"},{"id":"T196","span":{"begin":1199,"end":1203},"obj":"Disease"},{"id":"T197","span":{"begin":1484,"end":1492},"obj":"Disease"},{"id":"T198","span":{"begin":1493,"end":1502},"obj":"Disease"}],"attributes":[{"id":"A187","pred":"mondo_id","subj":"T187","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A188","pred":"mondo_id","subj":"T188","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A191","pred":"mondo_id","subj":"T191","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A193","pred":"mondo_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A194","pred":"mondo_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A195","pred":"mondo_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A196","pred":"mondo_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A197","pred":"mondo_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A198","pred":"mondo_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T171","span":{"begin":136,"end":138},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T172","span":{"begin":166,"end":169},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T173","span":{"begin":205,"end":210},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T174","span":{"begin":401,"end":403},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T175","span":{"begin":618,"end":624},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T176","span":{"begin":693,"end":695},"obj":"http://purl.obolibrary.org/obo/CLO_0001382"},{"id":"T177","span":{"begin":705,"end":707},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T178","span":{"begin":880,"end":886},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T179","span":{"begin":945,"end":957},"obj":"http://purl.obolibrary.org/obo/UBERON_0001969"},{"id":"T180","span":{"begin":1103,"end":1104},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T181","span":{"begin":1327,"end":1330},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T182","span":{"begin":1364,"end":1365},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T62","span":{"begin":54,"end":65},"obj":"Chemical"},{"id":"T63","span":{"begin":82,"end":87},"obj":"Chemical"},{"id":"T64","span":{"begin":155,"end":165},"obj":"Chemical"},{"id":"T65","span":{"begin":257,"end":268},"obj":"Chemical"},{"id":"T66","span":{"begin":272,"end":282},"obj":"Chemical"},{"id":"T67","span":{"begin":283,"end":287},"obj":"Chemical"},{"id":"T68","span":{"begin":760,"end":769},"obj":"Chemical"},{"id":"T69","span":{"begin":773,"end":784},"obj":"Chemical"},{"id":"T70","span":{"begin":1248,"end":1255},"obj":"Chemical"}],"attributes":[{"id":"A62","pred":"chebi_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A63","pred":"chebi_id","subj":"T63","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A64","pred":"chebi_id","subj":"T64","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A65","pred":"chebi_id","subj":"T65","obj":"http://purl.obolibrary.org/obo/CHEBI_3638"},{"id":"A66","pred":"chebi_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A67","pred":"chebi_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A68","pred":"chebi_id","subj":"T68","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"},{"id":"A69","pred":"chebi_id","subj":"T69","obj":"http://purl.obolibrary.org/obo/CHEBI_33281"},{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_53000"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T132","span":{"begin":0,"end":216},"obj":"Sentence"},{"id":"T133","span":{"begin":217,"end":405},"obj":"Sentence"},{"id":"T134","span":{"begin":406,"end":480},"obj":"Sentence"},{"id":"T135","span":{"begin":481,"end":709},"obj":"Sentence"},{"id":"T136","span":{"begin":710,"end":901},"obj":"Sentence"},{"id":"T137","span":{"begin":902,"end":1099},"obj":"Sentence"},{"id":"T138","span":{"begin":1100,"end":1210},"obj":"Sentence"},{"id":"T139","span":{"begin":1211,"end":1319},"obj":"Sentence"},{"id":"T140","span":{"begin":1320,"end":1508},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T543","span":{"begin":54,"end":65},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T544","span":{"begin":76,"end":81},"obj":"NCBITaxon:10239"},{"id":"T545","span":{"begin":82,"end":87},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T546","span":{"begin":112,"end":117},"obj":"NCBITaxon:10239"},{"id":"T547","span":{"begin":155,"end":165},"obj":"DG_28"},{"id":"T548","span":{"begin":205,"end":210},"obj":"NCBITaxon:10239"},{"id":"T549","span":{"begin":217,"end":227},"obj":"DG_28"},{"id":"T550","span":{"begin":257,"end":268},"obj":"DG_10;CHEBI:3638;CHEBI:3638"},{"id":"T551","span":{"begin":272,"end":287},"obj":"PR:000024939"},{"id":"T552","span":{"begin":314,"end":324},"obj":"SP_7"},{"id":"T553","span":{"begin":325,"end":336},"obj":"GO:0006260"},{"id":"T554","span":{"begin":425,"end":431},"obj":"NCBITaxon:10239"},{"id":"T555","span":{"begin":493,"end":505},"obj":"CHEBI:17154;CHEBI:17154"},{"id":"T556","span":{"begin":507,"end":516},"obj":"CHEBI:63580;CHEBI:63580;DG_29"},{"id":"T557","span":{"begin":518,"end":529},"obj":"CHEBI:7956;CHEBI:7956"},{"id":"T558","span":{"begin":531,"end":542},"obj":"CHEBI:119915;CHEBI:119915;DG_17"},{"id":"T559","span":{"begin":544,"end":553},"obj":"DG_30"},{"id":"T560","span":{"begin":555,"end":559},"obj":"PR:000003526"},{"id":"T561","span":{"begin":561,"end":572},"obj":"DG_41"},{"id":"T562","span":{"begin":578,"end":585},"obj":"DG_49"},{"id":"T563","span":{"begin":773,"end":784},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T564","span":{"begin":848,"end":858},"obj":"SP_7"},{"id":"T565","span":{"begin":880,"end":886},"obj":"NCBITaxon:9606"},{"id":"T566","span":{"begin":891,"end":895},"obj":"NCBITaxon:10088"},{"id":"T567","span":{"begin":945,"end":957},"obj":"UBERON:0001969"},{"id":"T568","span":{"begin":996,"end":1004},"obj":"SP_7"},{"id":"T569","span":{"begin":1153,"end":1161},"obj":"GO:0042571"},{"id":"T570","span":{"begin":1199,"end":1209},"obj":"SP_7"},{"id":"T571","span":{"begin":1237,"end":1245},"obj":"GO:0042571"},{"id":"T572","span":{"begin":1248,"end":1255},"obj":"BV_9"},{"id":"T573","span":{"begin":1291,"end":1295},"obj":"G_3;PG_10;PR:000003622"},{"id":"T574","span":{"begin":1437,"end":1447},"obj":"GO:0042571"},{"id":"T575","span":{"begin":1484,"end":1492},"obj":"SP_7"},{"id":"T27276","span":{"begin":54,"end":65},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T5576","span":{"begin":76,"end":81},"obj":"NCBITaxon:10239"},{"id":"T78132","span":{"begin":82,"end":87},"obj":"CHEBI:23888;CHEBI:23888"},{"id":"T34797","span":{"begin":112,"end":117},"obj":"NCBITaxon:10239"},{"id":"T81336","span":{"begin":155,"end":165},"obj":"DG_28"},{"id":"T90544","span":{"begin":205,"end":210},"obj":"NCBITaxon:10239"},{"id":"T7656","span":{"begin":217,"end":227},"obj":"DG_28"},{"id":"T83331","span":{"begin":257,"end":268},"obj":"DG_10;CHEBI:3638;CHEBI:3638"},{"id":"T49799","span":{"begin":272,"end":287},"obj":"PR:000024939"},{"id":"T8847","span":{"begin":314,"end":324},"obj":"SP_7"},{"id":"T97023","span":{"begin":325,"end":336},"obj":"GO:0006260"},{"id":"T81907","span":{"begin":425,"end":431},"obj":"NCBITaxon:10239"},{"id":"T18257","span":{"begin":493,"end":505},"obj":"CHEBI:17154;CHEBI:17154"},{"id":"T52332","span":{"begin":507,"end":516},"obj":"CHEBI:63580;CHEBI:63580;DG_29"},{"id":"T47704","span":{"begin":518,"end":529},"obj":"CHEBI:7956;CHEBI:7956"},{"id":"T49574","span":{"begin":531,"end":542},"obj":"CHEBI:119915;CHEBI:119915;DG_17"},{"id":"T61606","span":{"begin":544,"end":553},"obj":"DG_30"},{"id":"T43613","span":{"begin":555,"end":559},"obj":"PR:000003526"},{"id":"T67569","span":{"begin":561,"end":572},"obj":"DG_41"},{"id":"T1403","span":{"begin":578,"end":585},"obj":"DG_49"},{"id":"T10184","span":{"begin":773,"end":784},"obj":"CHEBI:33282;CHEBI:33282"},{"id":"T21946","span":{"begin":848,"end":858},"obj":"SP_7"},{"id":"T46433","span":{"begin":880,"end":886},"obj":"NCBITaxon:9606"},{"id":"T30825","span":{"begin":891,"end":895},"obj":"NCBITaxon:10088"},{"id":"T64508","span":{"begin":945,"end":957},"obj":"UBERON:0001969"},{"id":"T4651","span":{"begin":996,"end":1004},"obj":"SP_7"},{"id":"T50772","span":{"begin":1153,"end":1161},"obj":"GO:0042571"},{"id":"T19930","span":{"begin":1199,"end":1209},"obj":"SP_7"},{"id":"T75033","span":{"begin":1237,"end":1245},"obj":"GO:0042571"},{"id":"T85523","span":{"begin":1248,"end":1255},"obj":"BV_9"},{"id":"T66326","span":{"begin":1291,"end":1295},"obj":"G_3;PG_10;PR:000003622"},{"id":"T61832","span":{"begin":1437,"end":1447},"obj":"GO:0042571"},{"id":"T75491","span":{"begin":1484,"end":1492},"obj":"SP_7"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}

{"project":"2_test","denotations":[{"id":"32257431-31745213-54950110","span":{"begin":124,"end":126},"obj":"31745213"},{"id":"32257431-29511076-54950111","span":{"begin":212,"end":214},"obj":"29511076"},{"id":"32257431-31924756-54950112","span":{"begin":389,"end":391},"obj":"31924756"},{"id":"32257431-31924756-54950113","span":{"begin":687,"end":689},"obj":"31924756"},{"id":"32257431-31924756-54950114","span":{"begin":897,"end":899},"obj":"31924756"}],"text":"Initially, interferons-α nebulization, broad-spectrum antibiotics, and anti-viral drugs were used to reduce the viral load [49], [51], [52], however, only remdesivir has shown promising impact against the virus [53]. Remdesivir only and in combination with chloroquine or interferon beta significantly blocked the SARS-CoV-2 replication and patients were declared as clinically recovered [46], [50], [52]. Various other anti-virals are currently being evaluated against infection. Nafamostat, Nitazoxanide, Ribavirin, Penciclovir, Favipiravir, Ritonavir, AAK1, Baricitinib, and Arbidol exhibited moderate results when tested against infection in patients and in-vitro clinical isolates [46], [48], [50], [52]. Several other combinations, such as combining the antiviral or antibiotics with traditional Chinese medicines were also evaluated against SARS-CoV-2 induced infection in humans and mice [46]. Recently in Shanghai, doctors isolated the blood plasma from clinically recovered patients of COVID-19 and injected it in the infected patients who showed positive results with rapid recovery [54]. In a recent study, it was identified that monoclonal antibody (CR3022) binds with the spike RBD of SARS-CoV-2. This is likely due to the antibody’s epitope not overlapping with the divergent ACE2 receptor-binding motif. CR3022 has the potential to be developed as a therapeutic candidate, alone or in combination with other neutralizing antibodies for the prevention and treatment of COVID-19 infection [55]."}